Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence

Journal of Microbiology

Volumn 51, Issue 3, 2013, Pages 345-351

  Ko, Hui Ching ^a   Hsiao, Ting Yin ^a   Chen, Chiung Tong ^b   Yang, Yun Liang ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

drug susceptibility; enolase; hyphal formation; opportunistic human pathogen; virulence

Indexed keywords

ANTIFUNGAL AGENT; FUNGAL PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECT; GENETICS; MALE; METABOLISM; MOUSE; PATHOGENICITY; PHYSIOLOGY; SOUTHERN BLOTTING; VIRULENCE;

ANIMALS; ANTIFUNGAL AGENTS; BLOTTING, SOUTHERN; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; MALE; MICE; MICE, INBRED BALB C; VIRULENCE;

CANDIDA ALBICANS; MUS;

EID: 84879627876     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-013-2577-z     Document Type: Article

References (44)

1. Angiolella, L., Micocci, M. M., D'Alessio, S., Girolamo, A., Maras, B., and Cassone, A. 2002. Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance. Antimicrob. Agents Chemother. 46, 1688-1694.
2. Arguelles, J. C., Rodriguez, T., and Alvarez-Peral, F. J. 1999. Trehalose hydrolysis is not required for human serum-induced dimorphic transition in Candida albicans: evidence from a tps1/tps1 mutant deficient in trehalose synthesis. Res. Microbiol. 150, 521-529.
3. Baron, U., Gossen, M., and Bujard, H. 1997. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res. 25, 2723-2729.
4. Baron, U., Schnappinger, D., Helbl, V., Gossen, M., Hillen, W., and Bujard, H. 1999. Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes. Proc. Natl. Acad. Sci. USA96, 1013-1018.
5. Chen, C. G., Yang, Y. L., Cheng, H. H., Su, C. L., Huang, S. F., Chen, C. T., Liu, Y. T., Su, I. J., and Lo, H. J. 2006. Non-lethal Candida albicans cph1/cph1 efg1/efg1 transcription factor mutant establishing restricted zone of infection in a mouse model of systemic infection. Int. J. Immunopathol. Pharmacol. 19, 561-565.
6. Chen, C. G., Yang, Y. L., Tseng, K. Y., Shih, H. I., Liou, C. H., Lin, C. C., and Lo, H. J. 2009. Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans. Fungal Genet. Biol. 46, 714-720.
7. Chibana, H., Uno, J., Cho, T., and Mikami, Y. 2005. Mutation in IRO1 tightly linked with URA3 gene reduces virulence of Candida albicans. Microbiol. Immunol. 49, 937-939.
8. Clinical Laboratory Standards Institute (CLSI). 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27A, Wayne, PA, USA.
9. De Backer, M. D., Nelissen, B., Logghe, M., Viaene, J., Loonen, I., Vandoninck, S., de Hoogt, R., Dewaele, S., Simons, F. A., Verhasselt, P., andet al. 2001. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat. Biotechnol. 19, 235-241.
10. Eroles, P., Sentandreu, M., Elorza, M. V., and Sentandreu, R. 1997. The highly immunogenic enolase and Hsp70p are adventitious Candida albicans cell wall proteins. Microbiology143, 313-320.
11. Feo, S., Arcuri, D., Piddini, E., Passantino, R., and Giallongo, A. 2000. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett. 473, 47-52.
12. Jong, A. Y., Chen, S. H., Stins, M. F., Kim, K. S., Tuan, T. L., and Huang, S. H. 2003. Binding of Candida albicans enolase to plasmin (ogen) results in enhanced invasion of human brain microvascular endothelial cells. J. Med. Microbiol. 52, 615-622.
13. Keren, P., George, J., Shaish, A., Levkovitz, H., Janakovic, Z., Afek, A., Goldberg, I., Kopolovic, J., Keren, G., and Harats, D. 2000. Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. Diabetes49, 1064-1069.
14. Kim, R. Y. and Wistow, G. J. 1993. Expression of the duck alpha-enolase/tau-crystallin gene in transgenic mice. FASEB J. 7, 464-469.
15. Klingspor, L., Stintzing, G., and Tollemar, J. 1997. Deep Candida infection in children with leukaemia: clinical presentations, diagnosis and outcome. Acta Paediatr. 86, 30-36.
16. Lo, H. J., Kohler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., and Fink, G. R. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell90, 939-949.
17. Lo, H. J., Wang, J. S., Lin, C. Y., Chen, C. G., Hsiao, T. Y., Hsu, C. T., Su, C. L., Fann, M. J., Ching, Y. T., and Yang, Y. L. 2005. Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans. Antimicrob. Agents Chemother. 49, 1213-1215.
18. Mason, A. B., Buckley, H. R., and Gorman, J. A. 1993. Molecular cloning and characterization of the Candida albicans enolase gene. J. Bacteriol. 175, 2632-2639.
19. McAlister, L. and Holland, M. J. 1982. Targeted deletion of a yeast enolase structural gene. Identification and isolation of yeast enolase isozymes. J. Biol. Chem. 257, 7181-7188.
20. Miceli, M. H., Bernardo, S. M., and Lee, S. A. 2009. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int. J. Antimicrob. Agents34, 326-332.
21. Montagnoli, C., Sandini, S., Bacci, A., Romani, L., and La Valle, R. 2004. Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med. Mycol. 42, 319-324.
22. Nakayama, H., Mio, T., Nagahashi, S., Kokado, M., Arisawa, M., and Aoki, Y. 2000. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect. Immun. 68, 6712-6719.
23. Nesland, J. M., Holm, R., Johannessen, J. V., and Gould, V. E. 1988. Neuroendocrine differentiation in breast lesions. Pathol. Res. Pract. 183, 214-221.
24. Niedenthal, R., Riles, L., Guldener, U., Klein, S., Johnston, M., and Hegemann, J. H. 1999. Systematic analysis of S. cerevisiae chromosome VIII genes. Yeast15, 1775-1796.
25. Pitarch, A., Abian, J., Carrascal, M., Sanchez, M., Nombela, C., and Gil, C. 2004. Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics4, 3084-3106.
26. Plow, E. F. and Das, R. 2009. Enolase-1 as a plasminogen receptor. Blood113, 5371-5372.
27. Plow, E. F., Freaney, D. E., Plescia, J., and Miles, L. A. 1986. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103, 2411-2420.
28. Porter, J. D., Khanna, S., Kaminski, H. J., Rao, J. S., Merriam, A. P., Richmonds, C. R., Leahy, P., Li, J., and Andrade, F. H. 2001. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc. Natl. Acad. Sci. USA98, 12062-12067.
29. Reuss, O., Vik, A., Kolter, R., and Morschhauser, J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene341, 119-127.
30. Rudner, G., Katar, M., and Maisel, H. 1990. Enolase in the avian and turtle lens. Curr. Eye Res. 9, 139-150.
31. Sharkey, L. L., Liao, W. L., Ghosh, A. K., and Fonzi, W. A. 2005. Flanking direct repeats of hisG alter URA3 marker expression at the HWP1 locus of Candida albicans. Microbiology151, 1061-1071.
32. Sherman, F. 2002. Getting started with yeast. Methods Enzymol. 350, 3-41.
33. Sorger, D. and Daum, G. 2003. Triacylglycerol biosynthesis in yeast. Appl. Microbiol. Biotechnol. 61, 289-299.
34. Sundstrom, P. and Aliaga, G. R. 1992. Molecular cloning of cDNA and analysis of protein secondary structure of Candida albicans enolase, an abundant, immunodominant glycolytic enzyme. J. Bacteriol. 174, 6789-6799.
35. Sundstrom, P. and Aliaga, G. R. 1994. A subset of proteins found in culture supernatants of Candida albicans includes the abundant, immunodominant, glycolytic enzyme enolase. J. Infect. Dis. 169, 452-456.
36. Sung, H. J. and Cho, J. Y. 2008. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 41, 615-625.
37. Tremblay, P., Meiner, Z., Galou, M., Heinrich, C., Petromilli, C., Lisse, T., Cayetano, J., Torchia, M., Mobley, W., Bujard, H., andet al. 1998. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl. Acad. Sci. USA95, 12580-12585.
38. Trumbly, R. J. 1992. Glucose repression in the yeast Saccharomyces cerevisiae. Mol. Microbiol. 6, 15-21.
39. Tsuneki, H., Ishizuka, M., Terasawa, M., Wu, J. B., Sasaoka, T., and Kimura, I. 2004. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 4, 18.
40. van der Straeten, D., Rodrigues-Pousada, R. A., Goodman, H. M., and van Montagu, M. 1991. Plant enolase: gene structure, expression, and evolution. Plant Cell3, 719-735.
41. Xin, H., Dziadek, S., Bundle, D. R., and Cutler, J. E. 2008. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. USA105, 13526-13531.
42. Yang, Y. L., Chen, H. F., Kuo, T. J., and Lin, C. Y. 2006a. Mutations on CaENO1 in Candida albicans inhibit cell growth in the presence of glucose. J. Biomed. Sci. 13, 313-321.
43. Yang, Y. L., Lin, Y. H., Tsao, M. Y., Chen, C. G., Shih, H. I., Fan, J. C., Wang, J. S., and Lo, H. J. 2006b. Serum repressing efflux pump CDR1 in Candida albicans. BMC Mol. Biol. 7, 22.
44. Yang, Y. L., Wang, C. W., Chen, C. T., Wang, M. H., Hsiao, C. F., and Lo, H. J. 2009. Non-lethal Candida albicans cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells. Mycol. Res. 113, 388-390.